• CARsgen reported long-term follow-up results for satri-cel (CT041) in advanced gastric or gastroesophageal junction cancer at the 2026 ASCO meeting on May 30.
• The poster covered satri-cel used as sequential therapy following first-line treatment, positioning the program for earlier-line use in a key target market.
• China’s drug regulator accepted an NDA for satri-cel in June 2025 for Claudin18.2-positive advanced G/GEJA patients who failed at least two prior therapies.
• The filing holds Priority Review status plus Breakthrough Therapy Designation, supporting a potential faster path to market if the review is favorable.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260601-12178696), on June 01, 2026, and is solely responsible for the information contained therein.